Articles related to BREAST CANCER

Informed consent in breast cancer screening can lead to different choices: 20% of women in their 40s may choose to delay mammograms when presented with comprehensive risk-benefit information.

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.

IL-1B significantly influences breast cancer bone metastasis by promoting EMT, enhancing osteoclast activity, and creating a conducive metastatic niche. Targeting IL-1B in combination with standard therapies shows promising potential to reduce metastatic outgrowth.

Physicians are urged to navigate evolving breast cancer screening guidelines with caution, prioritizing patient-centered care amid shifting evidence landscapes.

The recent FDA approval of Lumicell’s breast cancer imaging system introduces a novel intraoperative tool that significantly enhances the precision of tumor resections, potentially reducing the need for subsequent corrective surgeries.

In an era where personalized treatment is paramount, the evolving landscape of axillary management in breast cancer stresses the shift towards minimizing surgical intervention while ensuring optimal patient outcomes.